

WEST Search History

[Hide Items](#)
[Restore](#)
[Clear](#)
[Cancel](#)

DATE: Sunday, April 02, 2006

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB,USPT,USOC; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L27	L25 and kringle	0
<input type="checkbox"/>	L26	L25 and kringle same (succinimidyl or maleimido)	0
<input type="checkbox"/>	L25	(514/19)[CCLS]	1753
	<i>DB=DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L24	0190970	25
<input type="checkbox"/>	L23	01090970	0
<input type="checkbox"/>	L22	2001090970	2
	<i>DB=USPT; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L21	6576610.pn.	1
	<i>DB=DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L20	9741824	2
<input type="checkbox"/>	L19	WO9741824	0
<input type="checkbox"/>	L18	199741824	0
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L17	wo009741824	0
<input type="checkbox"/>	L16	wo1997041824	0
<input type="checkbox"/>	L15	wo199741824	0
<input type="checkbox"/>	L14	97041824	1
<input type="checkbox"/>	L13	9041824	0
<input type="checkbox"/>	L12	wo97041824	0
<input type="checkbox"/>	L11	1997041824	0
<input type="checkbox"/>	L10	199741824	0
<input type="checkbox"/>	L9	wo 199741824	2487267
<input type="checkbox"/>	L8	L7 and kringle	2
<input type="checkbox"/>	L7	L6 and (succinimidyl or maleimido)	4
<input type="checkbox"/>	L6	davidson.in. and (succinimi\$ or maleimi\$)	18
<input type="checkbox"/>	L5	kringle.clm. and (succinimidyl or maleimido).clm.	0
<input type="checkbox"/>	L4	kringle same (succinimidyl or maleimido)	1
<input type="checkbox"/>	L3	kringle with (succinimidyl or maleimido)	1
<input type="checkbox"/>	L2	L1 and (succinimidyl or maleimido)	7
<input type="checkbox"/>	L1	(kringle with 5 with (protein or peptide)) with modif\$	8

END OF SEARCH HISTORY

FILE 'HOME' ENTERED AT 19:33:22 ON 02 APR 2006
-> b caplus uspatfull uspat2 pctfull biosis scisearch medline
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY 0.42
SESSION 0.42
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 19:34:20 ON 02 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 19:34:20 ON 02 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 19:34:20 ON 02 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 19:34:20 ON 02 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE 'BIOSIS' ENTERED AT 19:34:20 ON 02 APR 2006
Copyright (C) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 19:34:20 ON 02 APR 2006
Copyright (C) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 19:34:20 ON 02 APR 2006

-> s succinimidy and maleimid?
L1 11704 SUCCINIMIDYL AND MALEIMID?

-> s l1 and (coupl? or conjug?)
L2 11039 L1 AND (COUPL? OR CONJUG?)

-> s l2 and kringle
L3 405 L2 AND KRINGLE

-> dup remo l3
PROCESSING COMPLETED FOR L3
L4 377 DUP REMO L3 (28 DUPLICATES REMOVED)

-> s (succinimidy and maleimid?) (p) kringle
L5 126 (SUCCINIMIDYL OR MALEIMID?) (P) KRINGLE

-> s l5 (p) (coupl? or conjug?)
L6 114 L5 (P) (COUPL? OR CONJUG?)

-> dup remo l6
PROCESSING COMPLETED FOR L6
L7 110 DUP REMO L6 (4 DUPLICATES REMOVED)

-> s l7 and kringle (p) 5
L8 109 L7 AND KRINGLE (P) 5

-> s l8 and albumin
L9 76 L8 AND ALBUMIN

-> dup remo l9
PROCESSING COMPLETED FOR L9
L10 76 DUP REMO L9 (0 DUPLICATES REMOVED)

-> d l10 70-76 bib abs

L10 ANSWER 70 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 1996038557 PCTFULL ED 20020514
TIEN HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF
TIFR ANTAGONISTES DU RECEPTEUR DU FACTEUR DE CROISSANCE DES HEPATOCYTES ET

LEURS UTILISATIONS
SCHWALL, Ralph, H.;
TABOR, Kelly, Helen
GENENTECH, INC.;
SCHWALL, Ralph, H.;
TABOR, Kelly, Helen
English
Patent
WO 9638557
W:

AI 19961205
AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB
GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US
UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
CI CM CA GN ML MR NE SN TD TG

WO 1996-US8094
US 1995-8/460.368
Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, kits. Methods of treating cancer using the HGF receptor antagonists are also provided.

L'invention concerne des antagonistes du récepteur de croissance des hépatocytes (HGF), qui comportent des anticorps contre le récepteur HGF et des fragments de ceux-ci. Lesdits antagonistes du récepteur de HGF peuvent être utilisés pour bloquer la liaison du HGF aux récepteurs de HGF ou pour inhiber sensiblement l'activation du récepteur de HGF. Les antagonistes de HGF peuvent être intégrés dans des compositions pharmaceutiques, des articles manufacturés ou des trousseaux. L'invention porte également sur des méthodes de traitement du cancer au moyen desdits antagonistes du récepteur de HGF.

ANSWER 71 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1996015244 PCTFULL ED 20020514
SENSORY AND MOTOR NEURON DERIVED FACTOR (SMDF)
TIFR FACTEUR DERIVE DES NEURONES SENSORIELS ET MOTEURS (SMDF)
IN HO, Wei-Hsien;
OSHEROFF, Phyllis, L.
GENENTECH, INC.;
HO, Wei-Hsien;
OSHEROFF, Phyllis, L.
English
Patent
WO 9615244
W: CA JP MX US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT

SE
AI 1995-US14575
US 1994-8/339,517
Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic methods of preparing SMDF are disclosed. SMDF contains a 'beta'-type EGF-like domain and a N-terminal sequence which is distinct from all neuregulins reported so far. SMDF, when expressed in recombinant cell culture, activates tyrosine phosphorylation of the HER2/neu receptor in human breast cancer cells and displays mitogenic activity on Schwann cells. Northern blot and in situ hybridization analysis show that SMDF differs from other neuregulins in that it is nervous tissue specific, and is very highly

expressed, in comparison to other neuroregulins, in the human and rat spinal cord motor neurons and sensory neurons.
L'invention concerne le SMDF isole, un ADN isole codant pour le SMDF, et des procedes synthetiques ou de recombinaison pour preparer ce facteur. Ce dernier contient un domaine proche du facteur de croissance de l'epithelium du type 'beta' et une sequence N-terminale qui est distincte de toutes les neuroregulines decrites jusqu'a present. Lorsqu'il est recombinée, le SMDF active la phosphorylation de la tyrosine du recepteur HER2/neu dans les cellules humaines du cancer du sein et presente une activite mitogene sur les cellules de Schwann. Une analyse northern blot et par hybridation in situ revele que le SMDF differe des autres neuroregulines en ce qu'il est specifique des tissus nerveux, et est tres fortement exprime, par rapport aux autres neuroregulines, dans les neurones moteurs et les neurones sensoriels de la moelle epiniere de l'homme et du rat.

ABFR

ANSWER 72 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1996004004 PCTFULL ED 20020514
COMPOSITIONS AND METHODS FOR THE DELIVERY OF DRUGS BY PLATELETS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
COMPOSITIONS ET PROCES D'APPORT DE MEDICAMENTS PAR LES PLAQUETTES POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
GUREWICH, VICTOR
NEW ENGLAND DEACONESS HOSPITAL CORPORATION
English
Patent

ANSWER 73 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994006456 PCTFULL ED 20020513
HEPATOCYTE GROWTH FACTOR VARIANTS
VARIANTES DU FACTEUR DE CROISSANCE DES HEPATOCYTES
GODOWSKI, Paul, J.;
LOKKER, Nathalie, A.;
MARK, Melanie, R.;
GENENTECH, INC.;
GODOWSKI, Paul, J.;
LOKKER, Nathalie, A.;

ABFR

ANSWER 75 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1993023541 PCTFULL ED 20020513
HEPATOCYTE GROWTH FACTOR VARIANTS
VARIANTES DU FACTEUR DE CROISSANCE DES HEPATOCYTES
GODOWSKI, Paul, J.;
LOKKER, Nathalie, A.;
MARK, Melanie, R.;
GENENTECH, INC.;
GODOWSKI, Paul, J.;
LOKKER, Nathalie, A.;

ANSWER 77 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

ANSWER 78 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

PROTECTION AGAINST LIVER DAMAGE BY HGF
PROTECTION CONTRE DES LESIONS HEPATIQUES AU MOYEN DU FACTEUR DE CROISSANCE D'HEPATOCYTES (HGF)
ROOS, Filip;
SCHWALL, Ralph
GENENTECH, INC.;
ROOS, Filip;
SCHWALL, Ralph
English
Patent

ANSWER 79 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

ANSWER 80 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

ANSWER 81 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

ANSWER 82 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

ANSWER 83 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
1994000594 PCTFULL ED 20020513
METHODS FOR USING CKS FUSION PROTEINS
PROCEDES D'UTILISATION DES PROTEINES DE FUSION CKS
BOLLING, Timothy, J.;
DEVARÉ, Sushil, G.;
CASEY, James, M.;
DESAI, Suresh, M.;
ABBOTT LABORATORIES
English
Patent

aminophospholipides, ainsi que des
procedes servant a administrer de facon
therapeutiques, y compris des toxines
et des coagulants, aux aminophospholipides
d'expression stable de vaisseaux
sanguins tumoraux, ce qui provoque une
thrombose, une necrose et une regression de
la tumeur.

ANSWER 61 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
200002584 PCTFULL ED 20020515
TIFR CANCER TREATMENT METHODS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS
TIFR PROCES DE TRAITEMENT DU CANCER REPOSANT SUR L'UTILISATION D'ANTICORPS
IN VIS-A-VIS DES AMINOPHOSPHOLIPIDES
THORPE, Philip, E.;

PA RAN, Sophia
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
LA English
DT Patent
PI Patent
DS WO 2000002584

W: A2 20000120
AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LR LS LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW ZH GM
KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
CG CI CM GN GW ML MR NE SN TD TG

WO 1999-US15600 A 19990712
US 1998-60/092,672 19980713
US 1998-60/110,608 19981202
ABEN Disclosed are the surprising discoveries that aminophospholipids, such
as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible
on the luminal surface of tumor blood vessels, and that the administration of an
anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression
(in vivo). This invention therefore provides anti-aminophospholipid antibody-based methods and
compositions for use in the specific destruction of tumor blood vessels and in the treatment of
solid tumors. Although various antibody conjugates and combinations are thus provided, the use of
naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of
the invention, due to simplicity and effectiveness of the approach.

ABFR L'invention concerne la decouverte surprenante selon laquelle les
aminophospholipides, du type phosphatidylserine et phosphatidylethanolamine, sont des marqueurs
stables et accessibles a la surface intracavitare des vaisseaux sanguins de tumeur, et selon
laquelle la simple administration d'anticorps vis-a-vis des aminophospholipides suffit a induire la
thrombose, la necrose tumorale et la regression tumorale (in vivo). En consequence, l'invention concerne
des procedes reposant sur l'utilisation d'anticorps vis-a-vis des aminophospholipides, et des
compositions destinees a etre utilisees pour la destruction specifique des vaisseaux sanguins de
tumeur et le traitement des tumeurs solides. Bien que l'invention concerne ainsi plusieurs conjugues
et combinaisons d'anticorps, l'utilisation d'anticorps nus ou non conjugues vis-a-vis du
type phosphatidylserine est un aspect particulierement important de l'invention, grace a la
simplicite et a l'efficacite de l'approche consideree

ANSWER 62 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 1999046281 PCTFULL ED 20020515

TIFR NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
TIFR NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES LES CODANT
IN WOOD, William, I.;

GODDARD, Audrey;
GURNEY, Austin;
YUAN, Jean;
BAKER, Kevin, P.;

CHEN, Jian
GENENTECH, INC. ;
WOOD, William, I. ;
GODDARD, Audrey ;
GURNEY, Austin ;
YUAN, Jean ;
BAKER, Kevin, P. ;

LA English
DT Patent
PI Patent
DS WO 9946281

W: A2 19990916
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW ZH GM
KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
CI CM GN GW ML MR NE SN TD TG

WO 1999-US5028 A 19990308
US 1998-60/077,450 19980310
US 1998-60/077,632 19980311
US 1998-60/077,641 19980311
US 1998-60/077,649 19980312
US 1998-60/077,791 19980312
US 1998-60/078,004 19980313
US 1998-09/040,220 19980317
US 1998-60/078,886 19980320
US 1998-60/078,910 19980320
US 1998-60/078,939 19980320
US 1998-60/078,936 19980320
US 1998-60/079,294 19980325
US 1998-60/079,256 19980326
US 1998-60/079,728 19980327
US 1998-60/079,786 19980327
US 1998-60/079,664 19980327
US 1998-60/079,689 19980327
US 1998-60/079,663 19980327
US 1998-60/079,923 19980330
US 1998-60/079,920 19980330
US 1998-60/080,105 19980331
US 1998-60/080,165 19980331
US 1998-60/080,194 19980331
US 1998-60/080,107 19980331
US 1998-60/080,333 19980401
US 1998-60/080,327 19980401
US 1998-60/080,334 19980401
US 1998-60/080,328 19980401
US 1998-60/081,071 19980408
US 1998-60/081,070 19980408
US 1998-60/081,049 19980408
US 1998-60/081,195 19980409
US 1998-60/081,203 19980409
US 1998-60/081,229 19980409
US 1998-60/081,838 19980415
US 1998-60/081,955 19980415
US 1998-60/081,952 19980415
US 1998-60/081,817 19980415
US 1998-60/082,569 19980421
US 1998-60/082,568 19980421
US 1998-60/082,700 19980422
US 1998-60/082,804 19980422
US 1998-60/082,704 19980422

US 1998-60/082.767	AND METHODS OF USE THEREFOR	19980423	TIFR
US 1998-60/082.796	ANTICORPS SPECIFIQUES AU KRINGLE 5 DE	19980423	
US 1998-60/083.336	L'APOLIPOPROTEIN A ET PROCEDES D'UTILISATION A CET EFFET	19980427	IN
US 1998-60/083.322	KUNDU, Sumar, K.;	19980428	
US 1998-60/083.392	ZIEMANN, Robert	19980429	PA
US 1998-60/083.499	ABBOTT LABORATORIES	19980429	LA
US 1998-60/083.545	English	19980429	DT
US 1998-60/083.554	Patent	19980429	PI
US 1998-60/083.495	WO 9936784	19980429	DS
US 1998-60/083.558	CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT	19980429	
US 1998-60/083.496	SE	19980429	AI
US 1998-60/083.559	WO 1999-US1211	19980429	PRAI
US 1998-60/083.500	A 19990120	19980429	ABEN
US 1998-60/083.742	US 1998-60/072.924	19980430	
US 1998-60/084.366	The present invention provides monoclonal antibodies specific for	19980505	
US 1998-60/084.441	kringle 5 of apo(a) and	19980506	
US 1998-60/084.414	hydromas secreting such antibodies. The invention also relates to	19980506	
US 1998-60/084.640	assay methods for directly	19980507	
US 1998-60/084.640	measuring concentrations of lipoprotein(a) [Lp(a)] in a plasma sample.	19980507	
US 1998-60/084.639	In one embodiment, the method of Lp(a) from a plasma sample with a	19980507	
US 1998-60/084.637	involves the specific capture of Lp(a) from a plasma sample with a	19980507	
US 1998-60/084.643	monoclonal antibody developed	19980507	
US 1998-60/084.598	against kringle 5 of apo(a), which is	19980507	
US 1998-60/084.600	non-cross-reactive with plasminogen and kringle 4 of apo(a).	19980507	
US 1998-60/084.627	The quantity of the Lp(a) present in the sample is then measured by	19980507	
US 1998-60/085.339	detecting the amount of	19980513	
US 1998-60/085.338	Lp(a)-anti-kringle 5 complex that has formed in the	19980513	
US 1998-60/085.323	reaction. Alternatively, the Lp(a) may be	19980513	
US 1998-60/085.573	captured non-specifically and then detected with the monoclonal antibody	19980515	
US 1998-60/085.697	specific for kringle 5 of	19980515	
US 1998-60/085.580	apo(a). The invention also provides competitive assays using the	19980515	
US 1998-60/085.579	above-mentioned kringle 5 specific	19980515	
US 1998-60/085.704	monoclonal antibodies.	19980515	ABFR
US 1998-60/085.582	La presente invention concerne les anticorps monociaux specifiques du	19980515	
US 1998-60/085.689	kringle 5 de l'apo(a) et	19980515	
US 1998-60/085.700	les hydromes secretant de tels anticorps. L'invention concerne aussi	19980518	
US 1998-60/086.023	de mesurer les concentrations de lipoproteine (a) [Lp(a)] dans un	19980522	
US 1998-60/086.414	echantillon plasmatique. Dans un	19980522	
US 1998-60/086.392	mode de realisation, le procede implique la capture specifique d'une	19980522	
US 1998-60/086.430	Lp(a) a partir d'un echantillon	19980528	
US 1998-60/087.208	plasmatique avec un anticorps developpe contre le kringle	19980528	
US 1998-60/087.098	5 de l'apo(a), incapable d'une reactivite	19980730	
US 1998-60/087.106	croisee avec le plasminogene et le kringle 4 de l'apo(a). La	19980911	
US 1998-60/094.651	quantite de Lp(a) presente dans		
US 1998-60/100.038	l'echantillon est ensuite mesuree par la determination de la quantite de		
The present invention is directed to novel polypeptides and to nucleic	complexe de		
acid molecules encoding	Lp(a)-anti-kringle 5 qui s'est forme dans la		
those polypeptides. Also provided herein are vectors and host cells	reaction. Alternativement la Lp(a) peut etre capturee		
comprising those nucleic acid	non-specifiquement et ensuite detectee avec l'anticorps specifique du		
sequences, chimeric polypeptide molecules comprising the polypeptides of	kringle 5 de l'apo(a).		
the present invention fused	L'invention concerne aussi les analyses competitives mettant en oeuvre		
to heterologous polypeptide sequences, antibodies which bind to the	les anticorps monociaux		
polypeptides of the present	specifiques du kringle 5.		
invention and to methods for producing the polypeptides of the present			
invention.			
Cette invention, qui a trait a de nouveaux polypeptides et a des acides			
nucleiques les codant,			
concerne egalement des vecteurs et des cellules hotes renfermant ces			
sequences nucleotidiques, des			
sequences polypeptidiques chimeres renfermant les polypeptides de			
molecules polypeptidiques fusionnes a des			
l'invention fusionnes a des			
sequences polypeptidiques heterologues, ainsi que des anticorps se			
fixant a ces polypeptides.			
L'invention porte egalement sur des procedes de production de ces			
polypeptides.			
ANSWER 63 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN			
L10			
AN 1999036784 PCTFULL ED 20020515			
TIFR			
ANSWER 64 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN			
L10			
AN 1999032143 PCTFULL ED 20020515			
TIFR			
THROMBOGENIC POLYPEPTIDE CHIMERAS AND CONJUGATES HAVING ACTIVITY			
DEPENDENT UPON ASSOCIATION WITH TUMOR VASCULAR ENDOTHELIUM			
CHIMERES ET CONJUGUES POLYPEPTIDIQUES THROMBOGENES PRESENTANT UNE			
ACTIVITE DEPENDANT DE L'ASSOCIATION AVEC L'ENDOTHELIUM VASCULAIRE			
TUMORAL			
HOUSTON, L., L.;			
DICKINSON, Craig, D.			
NUVAS LLC;			
HOUSTON, L., L.;			
DICKINSON, Craig, D.			
English			
Patent			
WO 9932143			
Al 19990701			

DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW ZH ZM ZN ZZ
LA PRAI US 1997-08/796,744 A 19971223
ABEN Thrombois-initiating chimeric polypeptides and conjugates, where Figure 1 portrays one of the disclosed examples of the latter, are provided, as well as compositions comprising same and nucleic acid constructs encoding same. At least one component of a chimera or a conjugate is specific for one or more external features of the vascular endothelium of vessels nourishing a tumor and at least one thrombotic component is substantially inactive when not associated with said tumor vascular endothelium, permitting specific destruction of cancer cells of solid tumors in an animal.

ABFR L'invention concerne des polypeptides et des conjugués chimeres initiateurs de thrombose, un exemple de ces polypeptides et conjugués étant donné dans la Figure 1. L'invention concerne également des compositions renfermant ces polypeptides et ces conjugués, et des produits de recombinaison d'acide nucléique codant ces derniers. Au moins un constituant d'une chimère ou d'un conjugué est spécifique d'une ou plusieurs caractéristiques externes de l'endothélium vasculaire des vaisseaux entretenant un tumeur, et au moins un constituant thrombosant est sensiblement inactif si non associé à cet endothélium vasculaire tumoral, ce qui permet une destruction ciblée des tumeurs solides chez un animal.

L10 ANSWER 65 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 199805930 PCTFULL ED 20020514
TIEN METHODS FOR PRODUCING HETEROLOGOUS DISULFIDE BOND-CONTAINING POLYPEPTIDES IN BACTERIAL CELLS
TIFR PROCESSES OF PRODUCTION OF POLYPEPTIDES A PONTS DISULFURE HETEROLOGUES DANS DES CELLULES BACTERIENNES
IN QIU, Ji.;
PA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;
GENENTECH, INC.;
QIU, Ji.;
BESSETTE, Paul;
SWARTZ, James, R.
GENENTECH, INC.;
QIU, Ji.;
BESSETTE, Paul;
SWARTZ, James, R.
English
Patent
PI WO 9856930
LA A2 19981217
DT AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM GU HU ID IL IS JP KE KG KP KZ LC LK LR
LS LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW ZH ZM ZN ZZ
SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN ML MR NE SN TD TG
A 19980609
DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM GU HU ID IL IS JP KE KG KP KZ LC LK LR
LS LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW ZH ZM ZN ZZ
SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN ML MR NE SN TD TG
A 19980609
AI WO 1998-US12004
PRAI US 1997-08/871,483 19970609
ABEN Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments, the methods involve co-expression of a

prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator. L'invention concerne des procédés et des compositions destinés à la production de polypeptides a ponts disulfure hétérologues dans des cellules bactériennes. Dans des modes de réalisation préférés, les procédés en question font intervenir la co-expression d'une disulfure-isomérase de type procaryote (par exemple DsbC ou DsbG) et d'un gène codant un polypeptide eucaryote de recombinaison. Parmi les exemples de polypeptides donnés figure un activateur du plasminogène tissulaire.

L10 ANSWER 66 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 1998002541 PCTFULL ED 20020514
TIEN GAMMA-HERGULIN
TIFR GAMMA-HERGULINE
IN SCHAEFER, Gabrielle, M.;
SLIWKOWSKI, Mark
GENENTECH, INC.
English
Patent
PI WO 9802541
LA A1 19980122
DT AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH HU IL IS JP KE KG KP KZ LC LK LR LS LT LU
LV MD MG MK MN MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT UA UG UZ VN YU ZW ZH ZM ZN ZZ
AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE
IT LU MC NL PT SE BF BJ CF CG CI CM GN ML MR NE SN TD
TG
AI WO 1997-US11841 A 19970708
PRAI US 1996-60/021,640 19960712
ABEN A member of the heregulin superfamily has been identified which is designated 'gamma'-HRG. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. 'gamma'-HRG polypeptide and nucleic acid are disclosed, together with various uses thereof (e.g. use of 'gamma'-HRG nucleic acid for the recombinant production of 'gamma'-HRG). 'gamma'-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses thereof are also described. Un membre de la super famille des heregulines a été identifié et désigné 'gamma'-HRG. Cette molécule sécrétée par les cellules cancéreuses du sein MDA-MB-175, conduit à la formation d'un complexe de récepteur constitutif actif et stimule la croissance de ces cellules d'une manière autocrine. L'acide nucléique et le polypeptide de 'gamma'-HRG sont divulgués, ainsi que leurs utilisations (par exemple utilisation de l'acide nucléique 'gamma'-HRG pour la production recombinante de 'gamma'-HRG). L'invention décrit également des antagonistes de 'gamma'-HRG (p.ex. des anticorps de neutralisation et des molécules d'acides nucléiques antisens) ainsi que leurs utilisations.

L10 ANSWER 67 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 1997038123 PCTFULL ED 20020514
TIEN METHODS FOR PRODUCING SOLUBLE, BIOLOGICALLY-ACTIVE DISULFIDE BOND-CONTAINING EUKARYOTIC PROTEINS IN BACTERIAL CELLS
TIFR PROCESSES OF PRODUCTION OF PROTEINES EUKARYOTES, SOLUBLES, ACTIVES SUR

PLAN BIOLOGIQUE ET CONTENANT DES LIAISONS DISULFURE, A L'INTERIEUR DE CELLULES BACTERIENNES

IN GEORGIOU, George;
PA OSTERMEIER, Marc
LA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DT English
PI Patent
DS WO 9738123

AL 19971016
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GH GU HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ
TM TR TT UA UG UZ VN YU YE ZL ZM ZN ZZ
KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM CA GN ML MR NE SN TD TG

WO 1997-05636
US 1996-60/014,950 A 19960405
Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.

Cette invention concerne des procedes de production de polypeptides eucaryotes, solubles, qui sont actifs sur plan biologique et qui contiennent des liaisons disulfure, ceci a l'interieur d'hotes bacteriens. Cette invention, qui concerne egalement les compositions ainsi obtenues, a permis de demontrer la co-expression d'une foldase eucaryote et d'un polypeptide contenant une liaison disulfure a l'interieur d'une cellule bacterienne hote. Dans des modes de realisation particuliers, ces procedes ont permis de produire un inhibiteur de trypsin pancreatique chez les mammiferes ainsi qu'un activateur plasminogene de tissus (tPA), lesquels se presentent sous des formes solubles, actives sur le plan biologique, et pouvant etre isolees du periplasme bacterien.

Cette invention concerne enfin des systemes d'expression, des vecteurs recombinants, ainsi que des cellules hotes transformees.

ANSWER 68 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 1997035885 PCTFULL ED 20020514
TIEN ERBB3 ANTIBODIES
TIFR ANTICORPS DE LA PROTEINE Erbb3
IN AKITA, Robert;
PA SLIWOMSKI, Mark
LA GENENTECH, INC.
DT Patent
PI WO 9735885

AL 19971002
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GH GU HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV
MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM
TR TT UA UG UZ VN YU YE ZL ZM ZN ZZ
RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE BF BJ CF CG CI CM CA GN ML MR NE SN TD TG

WO 1997-053546
US 1996-8/624,036 A 19960327
Antibodies are disclosed which bind to Erbb3 protein and further possess any one or more of the

following properties: an ability to reduce heregulin-induced formation of an Erbb2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3.

L'invention a trait a des anticorps se fixant a la proteine ErbB3 et qui possedent, en outre, l'une des proprietes suivantes ou avantage: aptitude a reduire la formation, induite par l'hereguline, d'un complexe proteique ErbB2-ErbB3 dans une cellule qui exprime les proteines ErbB2 et ErbB3, aptitude a accroitre l'affinite de fixation de l'hereguline pour la proteine ErbB3 et pour la proteine ErbB2 et pouvoir de reduire l'activation de la proteine ErbB2 induite par l'hereguline dans une cellule qui exprime les proteines ErbB2 et ErbB3.

ANSWER 69 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 1997017371 PCTFULL ED 20020514
TIEN ISOLATION OF apo(a), COMPOSITIONS, AND METHODS OF USE
TIFR ISOLATION OF L'apo(a), COMPOSITIONS ET PROCESSES D'UTILISATION
IN SCANU, Angelo, M.;
PA EDELSTEIN, Celina
LA ARCH DEVELOPMENT CORPORATION
DT English
PI Patent
DS WO 9717371

AL 19970515
AL AM AT AU BA BB BG CA CH CN CU CZ DE DK EE ES FI GB GE
HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK
MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA
UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT
BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
CG CI CM CA GN ML MR NE SN TD TG

WO 1996-US18136 A 19961108
US 1995-60/006,395 19951109
US 1996-8/691,795 19960802

Disclosed are novel compositions comprising purification of active apolipoprotein (a), apo(a), derived from Lp(a). Also disclosed are methods for determining elastase activity and methods for screening for inhibitors of elastase activity. Methods are also disclosed for purifying, quantitating, and reconstituting active lipoprotein(a), Lp(a). On obtient de nouvelles compositions impliquant la purification de l'apolipoproteine (a), apo(a), derivee de Lp(a). On decrit des procedes permettant de determiner l'activite elastase, et enfin des procedes de purification, quantification et reconstitution de lipoproteine (a) active, Lp(a).

(FILE 'HOME' ENTERED AT 19:33:22 ON 02 APR 2006)

FILE 'CAPLUS, USPATFULL, USPAT2, PCTFULL, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 19:34:20 ON 02 APR 2006

L1 11704 S SUCCINIMIDYL AND MALEIMID?
L2 11039 S L1 AND (COUPL? OR CONJUG?)
L3 405 S L2 AND KRINGLE
L4 377 DUP REMO L3 (28 DUPLICATES REMOVED)
L5 126 S (SUCCINIMIDYL OR MALEIMID?) (P) KRINGLE
L6 114 S L5 (P) (COUPL? OR CONJUG?)
L7 110 DUP REMO L6 (4 DUPLICATES REMOVED)
L8 109 S L7 AND KRINGLE (P) 5

-> d his

L9 76 S L8 AND ALBUMIN
 L10 76 DUP REMO L9 (0 DUPLICATES REMOVED)
 => b medline biosis scisearch
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 FILE 'MEDLINE' ENTERED AT 19:39:45 ON 02 APR 2006
 FILE 'BIOSIS' ENTERED AT 19:39:45 ON 02 APR 2006
 Copyright (c) 2006 The Thomson Corporation
 FILE 'SCISEARCH' ENTERED AT 19:39:45 ON 02 APR 2006
 Copyright (c) 2006 The Thomson Corporation
 => s l10
 L11 0 L10
 => s l8
 L12 0 L8
 => s l6
 L13 3 L6
 => dup remo l13
 PROCESSING COMPLETED FOR L13
 L14 1 DUP REMO L13 (2 DUPLICATES REMOVED)
 => d l14 bib abs
 L14 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1
 AN 2004122095
 DN PubMed ID: 15012978
 TI Kringle 5 peptide-albumin conjugates with anti-migratory activity.
 AU Leger Roger; Benquet Corinne; Huang Xicai; Quraishi Omar; van Wyk Pieter;
 Bridon Dominique
 CS Research Department, ConjuChem Inc., 225 President-Kennedy Ave., Suite
 3950, Montreal, QC, H2X 3Y8 Canada. leger@conjuchem.com
 SO Bioorganic & medicinal chemistry letters, (2004 Feb 23) Vol. 14, No. 4,
 pp. 841-5.
 Journal code: 9107377. ISSN: 0960-894X.
 England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200409
 ED Entered STN: 20040312
 Last Updated on STN: 20040929
 Entered Medline: 20040928
 AB Three peptide fragments of the kringle 5 region of plasminogen
 and their respective N- and C-terminus maleimido derivatives
 conjugated to Cys34 of human serum albumin were evaluated in vitro
 using a human umbilical vein endothelial cell (HUVEC) migration assay and
 a human plasma stability assay. The N-terminus maleimido
 derivative of the 64 to 74 segment of kringle 5
 conjugated to human serum albumin possessed remarkable
 anti-migratory activity.

=>